We are live on ! Find out more
PC

Polar Capital Portfolio holdings

AUM $13.5B
1-Year Est. Return 55.9%
This Fund
S&P 500
This Quarter Est. Return
+7.6%
1 Year Est. Return
+55.9%
3 Year Est. Return
+127.44%
5 Year Est. Return
+269.08%
10 Year Est. Return
–
AUM
$8.89B
AUM Growth
+$1.45B
Cap. Flow
+$1.09B
Cap. Flow %
12.29%
Top 10 Hldgs %
26.12%
Holding
266
New
39
Increased
114
Reduced
52
Closed
27

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$63.8M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$50M
3
VR
Validus Hold Ltd
VR
+$44.1M
4
PBYI icon
Puma Biotechnology
PBYI
+$33.5M
5
BIO icon
Bio-Rad Laboratories Class A
BIO
+$30.4M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$59.3M
2
DHR icon
Danaher
DHR
+$44.2M
3
HOLX
Hologic
HOLX
+$42M
4
BDX icon
Becton Dickinson
BDX
+$40.7M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$38.7M

Sector Composition

Rank Sector Weight
1 Financials 21.97%
2 Healthcare 21.33%
3 Technology 19.13%
4 Communication Services 9.13%
5 Industrials 6.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCHW
76
Charles Schwab
SCHW
$177B
$38.5M 0.43%
880,555
+517,683
+143% +$21.5M
DVAX
77
DELISTED
Dynavax Technologies
DVAX
$37.6M 0.42%
+1,750,000
New +$27.7M
BOX icon
78
Box
BOX
$4.02B
$37.6M 0.42%
1,946,390
+155,900
+9% +$2.93M
CGNX icon
79
Cognex
CGNX
$10.3B
$37.4M 0.42%
678,756
-35,156
-5% -$1.79M
RGA icon
80
Reinsurance Group of America
RGA
$15.7B
$37.4M 0.42%
268,000
+5,500
+2% +$744K
ANET icon
81
Arista Networks
ANET
$219B
$37.3M 0.42%
3,150,000
-166,800
-5% -$1.74M
LITE icon
82
Lumentum
LITE
$59.4B
$36.7M 0.41%
675,796
+337,001
+99% +$19.6M
RNR icon
83
RenaissanceRe
RNR
$13.7B
$36.5M 0.41%
270,000
+45,700
+20% +$6.43M
BAH icon
84
Booz Allen Hamilton
BAH
$8.7B
$35.8M 0.4%
957,718
– –
ABMD
85
DELISTED
Abiomed Inc
ABMD
$35.4M 0.4%
210,000
– –
ACRS icon
86
Aclaris Therapeutics
ACRS
$730M
$34.7M 0.39%
1,346,049
– –
ICLR icon
87
Icon
ICLR
$12.8B
$34.4M 0.39%
302,045
– –
TRV icon
88
Travelers Companies
TRV
$80.8B
$34M 0.38%
277,500
+60,450
+28% +$7.55M
CPA icon
89
Copa Holdings
CPA
$5.56B
$32.6M 0.37%
261,976
-74,673
-22% -$9.44M
LRCX icon
90
Lam Research
LRCX
$382B
$32.6M 0.37%
1,759,940
– –
CI icon
91
Cigna
CI
$76.6B
$31.8M 0.36%
170,000
-136,268
-44% -$24.3M
PTLA
92
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$31.8M 0.36%
588,200
+250,700
+74% +$14.7M
EA icon
93
Electronic Arts
EA
$52.4B
$31.6M 0.36%
267,468
+3,300
+1% +$382K
IPG
94
DELISTED
Interpublic Group of Companies
IPG
$31.2M 0.35%
1,501,704
– –
SEM
95
DELISTED
Select Medical
SEM
$31M 0.35%
+2,995,300
New +$27.7M
AKAO
96
DELISTED
Achaogen Inc
AKAO
$30.3M 0.34%
1,902,458
+441,962
+30% +$8.41M
PEN icon
97
Penumbra
PEN
$12.5B
$30.1M 0.34%
333,630
+20,000
+6% +$1.72M
BIO icon
98
Bio-Rad Laboratories Class A
BIO
$8.42B
$30M 0.34%
+135,195
New +$30.4M
ILMN icon
99
Illumina
ILMN
$29.4B
$29.9M 0.34%
+154,470
New +$28.8M
AABA
100
DELISTED
Altaba Inc
AABA
$28.7M 0.32%
+433,562
New +$26.6M
2 3
4
5 6

Similar funds

ECM
ETrade Capital Management Arlington, Virginia $5.37B AUM 10.84% 1-Year Est. Return
FAAS
First Allied Advisory Services San Diego, California $2.98B AUM 15.89% 1-Year Est. Return
WAM
Wealthspire Advisors (Maryland) Potomac, Maryland $2.84B AUM 10.91% 1-Year Est. Return
FS
Feinberg Stephen $2.61B AUM 15.12% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
TI
TT International London, United Kingdom $1.94B AUM
VIM
Veritas Investment Management London, United Kingdom $1.65B AUM 25.54% 1-Year Est. Return
PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Polar Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Polar Capital held 266 positions worth $8.89B, up 20% from $7.43B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Polar Capital deployed $1.09B of net new capital in Q3 2017, opening 39 new positions and adding to 114 existing holdings. Its largest new stake was Puma Biotechnology: 360,000 shares worth $43.1M.

By sector, the portfolio is most concentrated in Financials at 22% of assets, down from 23% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Medtronic, an estimated $59.3M trimmed.

  • Polar Capital's largest Q3 2017 buy was Puma Biotechnology: 360,000 shares worth $43.1M.
  • Polar Capital added most to Amgen in Q3 2017, an estimated $63.8M increase.
  • Polar Capital's biggest Q3 2017 reduction was Medtronic, cutting an estimated $59.3M.
  • Polar Capital fully exited Hologic in Q3 2017, selling an estimated $42M.
  • Polar Capital's ten largest holdings make up 26% of its $8.89B portfolio in Q3 2017.
  • Polar Capital opened 39 new positions and closed 27 in Q3 2017.
  • Polar Capital's portfolio value rose 20% quarter-over-quarter to $8.89B.

Based on Polar Capital's 13F filing for Q3 2017, filed 14 Nov 2017.